Amylyx Pharmaceuticals, Inc. AMLX 深 沪
已收盘 02-06 16:00:00 美东时间
13.98
+0.990
+7.62%
华盛通- 最 高14.08
- 今 开13.35
- 成交量 93.39万股
- 最 低 13.27
- 昨 收 12.99
- 总市值 15.35亿
- 52周最高 17.49
- 市盈率 静 --
- 换手率 0.85%
- 52周最低 2.60
- 委 比 -37.90%
- 总股本 1.10亿
- 历史最高 41.9297
- 量 比 0.71
- 振 幅 6.24%
- 历史最低 1.575
- 每 手 1
- 风险率 4.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Amylyx Pharmaceuticals Selects AMX0318 As Novel Long-Acting GLP-1 Receptor Antagonist Development Candidate Through Gubra Collaboration
AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high solubility, and a
01-08 20:14
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 10:22
HC Wainwright & Co. Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $20
HC Wainwright & Co. analyst Andrew Fein maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $16 to $20.
2025-11-08 03:52
Amylyx Pharma Q3 EPS $(0.37) Beats $(0.45) Estimate
Amylyx Pharma (NASDAQ:AMLX) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.45) by 17.04 percent. This is a 30.19 percent increase over losses of $(0.53) per share from the
2025-11-06 20:04
美股大行评级 | 潜在最高涨幅37.45%，甲骨文获多家机构上调目标价；瑞穗上调美光科技目标价升至240美元
今日重点评级关注：韦德布什：维持Artiva Biotherapeutics"跑赢大市"评级，目标价从18美元升至23美元；巴克莱：维持Cellectis"超配"评级，目标价从4美元升至8美元
2025-10-20 10:03
美股大行评级 | Needham上调台积电目标价升至360美元！美国银行、摩根士丹利分别获多家机构上调目标价
今日重点评级关注：Rosenblatt：维持HIVE Digital Technologies"买入"评级，目标价从5美元升至10美元；摩根大通：维持Array Technologies"超配"评级，目标价从13美元升至15美元
2025-10-17 09:58
Baird Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $19
Baird analyst Joel Beatty maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $10 to $19.
2025-10-16 19:30
美股大行评级 | 潜在涨幅1176.6%！Ascendiant Capital上调Society Pass目标价至18美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从15美元升至18美元；Ascendiant Capital：维持Surgepays"买入"评级，目标价从9美元升至9.5美元
2025-10-06 08:35
B of A Securities Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $16
B of A Securities analyst Geoff Meacham maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $14 to $16.
2025-10-03 21:06
